Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq:SNOA) has announced the launch of its HOCl-based diaper rash product in major U.S. retail channels. The antimicrobial hydrogel, based on their patented Microcyn® technology, is now available in 3,600 Walmart stores, Amazon.com, and various large grocery chains.

This launch marks Sonoma's strategic expansion into the over-the-counter consumer market, offering their stabilized hypochlorous acid (HOCl) technology directly to consumers seeking solutions for diaper rash and skin irritations. The product is being distributed through their U.S.-based distribution partner.

Positive

• Significant retail presence with distribution in 3,600 Walmart stores
• Expansion into major e-commerce platform Amazon.com
• Strategic entry into over-the-counter consumer market
• Leveraging existing Microcyn technology for new consumer applications

Negative

• None.

BOULDER, CO / ACCESS Newswire / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its HOCl-based diaper rash product for infants and children into large retailers in the United States.

The antimicrobial hydrogel is being marketed and sold through Sonoma's U.S.-based distribution partner. The diaper rash product is currently carried in 3,600 Walmart stores, Amazon.com, and certain large grocery chains.

"We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma. "We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations."

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com

Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

Where can I buy Sonoma Pharmaceuticals (SNOA) diaper rash product?

The product is available in 3,600 Walmart stores, Amazon.com, and certain large grocery chains across the United States.

What technology does Sonoma Pharmaceuticals use in their diaper rash product?

The product uses Sonoma's patented Microcyn® technology, which is based on stabilized hypochlorous acid (HOCl).

What is the significance of SNOA's diaper rash product launch?

This launch represents Sonoma's strategic expansion into the over-the-counter consumer market, marking their first U.S. consumer product in large-scale retail channels.

How is Sonoma Pharmaceuticals distributing their new diaper rash product?

The product is being marketed and sold through Sonoma's U.S.-based distribution partner to major retailers including Walmart and Amazon.